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Editorial
Overdiagnosis is the diagnosis of deviations, abnormalities, risk factors, and pathologies that in themselves 
would never cause symptoms (this applies only to risk factors and pathology), would never lead to morbidity, and 
would never be the cause of death. Therefore, treating an overdiagnosed condition (deviation, abnormality, risk 
factor, pathology) cannot, by definition, improve the patient’s prognosis, and can therefore only be harmful. 
Overdiagnosis is an extremely harmful and big problem all over the world, and the problem is increasing. This 
is especially the case in high-income countries, where more sensitive tests, more testing, more screening 
and earlier diagnosis is in focus, and more of the same will be implemented in the future. Moreover, disease 
definitions have been and are still being widened, plus thresholds for treating, e.g. risk factors, have been and 
are still being lowered. Finally, disease mongering is growing, because it is cheaper and faster to invent new 
“diseases” than new pharmaceutical drugs.
From the definition of overdiagnosis it can be reasoned that a patient who has been correctly diagnosed and 
a person who has been overdiagnosed can have the same kind of pathologies. Therefore, at the level of the 
individual person or patient it can never be verified whether he or she has in fact been correctly diagnosed or 
overdiagnosed. Therefore, the complexity, dilemmas and pitfalls in understanding what overdiagnosis really is 
so succinctly captured by this quote from the Danish philosopher Søren Kirkegaard (1813-55): ‘Life can only be 
understood backwards; but it must be lived forwards’.
Postavljanje nepotrebne diagnoze je diagnosticiranje odstopanj, nepravilnosti, dejavnikov tveganja in 
patologij, ki same po sebi nikoli ne povzročajo simptomov (to se nanaša le na dejavnike tveganja in patologije), 
nikoli ne prehajajo v bolezen ter niso nikoli vzrok za smrt osebe. S tega vidika zdravljenje zmotno prepoznanega 
stanja (odstopanje, nepravilnost, dejavnik tveganja, patologija) po sami definiciji ne more izboljšati napovedi 
pacientovega zdravja ter mu lahko le škoduje.
Prediagnosticiranje je izjemno škodljiva in razširjena težava v svetu, sam pojav pa se hitro širi. Predvsem 
je prisotno v državah z visokimi prihodki, kjer izvajajo presejalne programe, več vrst testiranj in imajo 
občutljivejše teste, v ospredju pa je predvsem zgodnje odkrivanje bolezni in postavljanje diagnoze. V 
prihodnosti bo tega vse več. Definicije bolezni se vse bolj razširjajo, meje začetka zdravljenja, na primer 
dejavnikov tveganja, se pa še vedno nižajo. Napihovanje bolezni je vse pogostejše, saj je ceneje in hitreje 
ustvariti nove »bolezni« kot izdelati nova farmacevtska zdravila. 
Iz same definicije je prediagnosticiranje lahko upravičeno le tako, da imata pacient s pravilno diagnozo in 
oseba, ki so ji postavili napačno diagnozo, enako vrsto patologij. Tako lahko na stopnji posameznih pacientov 
ugotovimo in preverimo, če so prejeli pravilno ali pretirano diagnozo. Zapletene dileme in pasti pri razumevanje 
postavljanja zmotne diagnoze je zelo jedrnato povzeto v citatu danskega filozofa Sørna Kirkegaarda (1813–
1855): »Življenje lahko razumemo samo za nazaj, živeti pa ga je treba naprej«.
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Overdiagnosis is the diagnosis of deviations, abnormalities, 
risk factors, and pathologies that in themselves would 
never cause symptoms (this applies only to risk factors 
and pathology), would never lead to morbidity, and would 
never be the cause of death (1). Therefore, treating an 
overdiagnosed condition (deviation, abnormality, risk 
factor, pathology) cannot, by definition, improve the 
patient’s prognosis, and can therefore only be harmful 
(2). Overdiagnosis is often mistaken from overtreatment 
and overuse; however, these are three separate 
concepts with some overlap: Treatment of overdiagnosed 
conditions is one category of overtreatment. Another 
type of overtreatment is when the best available 
scientific evidence shows that the treatment has no 
beneficial effect(s) on the diagnosed condition and 
may even be harmful (3). Overuse, better described as 
overutilisation, is the ‘establishment of standard practice 
in health services or systems that do not provide net 
benefit to patients or citizens’ (3). Overutilisation does 
not necessarily lead to overdiagnosis or overtreatment, 
but the risk increases proportionally with the degree 
of overutilisation. When discussing the three concepts 
(overdiagnosis, overtreatment and overuse), it should be 
recognised that they can have different causes and drivers 
as to why they appear, and especially the consequences 
of overdiagnosis, overtreatment and overuse can be very 
different.
Overdiagnosis is an extremely harmful and big problem 
all over the world, and the problem is increasing. This is 
especially the case in high-income countries, where more 
sensitive tests, more testing, more screening and earlier 
diagnosis are in focus, and more of the same will be 
implemented in the future. Moreover, disease definitions 
have been, and are still being, widened, plus thresholds 
for treating, for example, risk factors have been, and are 
still being, lowered. Finally, disease mongering is growing, 
because it is cheaper and faster to invent new “diseases” 
than new pharmaceutical drugs. 
From the definition of overdiagnosis it can be reasoned that 
a patient who has been correctly diagnosed and a person 
who has been overdiagnosed can have the same kind of 
deviations, abnormalities, risk factors or pathologies. 
Therefore, at the level of the individual person or patient, 
it can never be verified whether he or she has in fact been 
correctly diagnosed or overdiagnosed. Only at the end 
of the patient’s life we can, for biomedical conditions, 
confirm whether the diagnosis was correct or iatrogenic. 
With respect to psychosocial conditions, illnesses and 
mental disorders, we can never, at the individual level, 
answer the question conclusively: Correctly diagnosed 
or overdiagnosed? Therefore, the complexity, dilemmas 
and pitfalls in understanding what overdiagnosis really 
is so succinctly captured by this quote from the Danish 
philosopher Søren Kirkegaard (1813-55): ‘Life can only be 
understood backwards; but it must be lived forwards’. 
Overdiagnosis can be investigated both in phenomeno-
logical perspectives and in epidemiological designs.
Using a phenomenological perspective, informants who 
are most likely overdiagnosed or informants that have had 
the experience of being overdiagnosed (false positives) 
for a short period of time can be interviewed: Hansson et 
al. interviewed 15 men who, via screening, were (over)
diagnosed with an abdominal aortic aneurism (AAA) with 
a median aorta-diameter of 32 mm (4). The AAA was by 
some of the men described as “a ticking bomb inside your 
stomach” (4). Another example from a qualitative study 
was focus group interviews with lung cancer CT screening 
participants who had had an abnormal screening result 
later confirmed to be false positive (5). In the critical 
period (the time period of three months or more from 
when the abnormal screening result was acknowledged 
to the point in time the screening participant was 
cleared of suspicion of lung cancer), these screening 
participants reported substantial negative psychosocial 
consequences from living with the uncertainty of possibly 
having lung cancer (5). The final example is a mixed-
methods study, using a phenomenologically-based patient 
reported outcome measure, quantifying the psychosocial 
consequences of a false-positive screening mammography, 
in which more than 1,300 women were included (6). This 
study revealed that the women still reported substantial 
negative psychosocial consequences three years after the 
false-positive screening result (6). 
A simple and very robust way to estimate the degree of 
overdiagnosis in a screening RCT (randomised controlled 
trial) would be to estimate the cumulative incidence of 
the condition screened for in the intervention group and 
in the control group (7). However, two types of biases 
are of importance: lead-time bias and contamination 
of the control group. A very didactical example of this 
is the European Randomized Study of Screening for 
Prostate Cancer (ERSPC): after 9 years of follow-up, the 
ratio between one prevented death of prostate cancer 
and men overdiagnosed with prostate cancer was 1:47, 
while this ratio decrease to 1:37 at the 11-year follow-up, 
and to 1:27 after 13 years of follow-up (8-10). Here it is 
obvious that lead-time is of importance; however, more 
than 20% of the men in control also had a PSA test in the 
ERSPC. These two biases, respectively, underestimate and 
overestimate the degree of overdiagnosis. Therefore, the 
“true” degree of overdiagnosis is hard to assess; however, 
it is substantial in PSA screening. 
Harris and colleagues have suggested a taxonomy 
describing seven different categories of harms of screening 
that could be explored, namely: finan¬cial strain, hassles/
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inconveniences, medical costs, op¬por¬tu¬nity costs, 
physical harms, psy¬cholo¬gi-cal harms, and societal costs 
(11). In addition, we have identified empirical evidence 
for an additional category: work-related costs (12). These 
eight different categories of harms could also be applied 
to research about harms of overdiagnosis. 
In many aspects of overdiagnosis, there is a substantial 
absence of scientific evidence, e.g. cancer screening 
(13). Internationally, there is, however, a growing 
awareness and interest in research about overdiagnosis, 
especially how to prevent it (14). But before we can 
answer this questions of how to decrease and prevent 
overdiagnosis, much more research is needed, e.g. 
about: the causes and drivers of overdiagnosis; the harms 
of overdiagnosis; the consequences of overdiagnosis; 
and how to communicate overdiagnosis to physicians, 
other healthcare professionals, politicians, healthcare 
providers and stakeholders, and most importantly, the 
general population.
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